Probiotics in Metabolic Disorder Treatment

Microbial consortia for effectively treating conditions related to metabolic disease by efficiently breaking down and metabolizing disease-associated substrates. The consortia contain a group of active microbes that degrade the substrate causing the disease, along with a supportive community of microbes that optimize the active microbes' growth and metabolism. The supportive community enhances characteristics like engraftment, biomass, stability of the active microbes. The consortium can degrade substrates like phenylalanine, tyrosine, bile acids, and pathogenic carbohydrates.

Source

Using inactivated Lactobacillus casei I0B-P9 and its postbiotics to reduce blood glucose and improve dyslipidemia in diabetics.

Source

A method for treating type 2 diabetes (T2D) by modulating a subject's microbiota composition away from that associated with a Western diet and toward one conferring the benefits of a plant-based diet. The method involves administering probiotics and prebiotics to improve the gut microbiome, with strains shown to be beneficial in studies of diabetes and obesity. The microbial compositions can be customized based on an individual's microbiome profile and contain specific bacteria and fungi identified from plants.

Source

Using a specific strain of Lactobacillus rhamnosus called CMU-pb-7 isolated from feces, to prepare blood lipid-lowering drugs. The strain can relieve impaired glucose tolerance caused by a high-fat diet in mice with hyperlipidemia, reduce the blood lipid level, enhance the antioxidant capacity of the liver tissue, and regulate the expression of key proteins of liver lipid metabolism to relieve fatty change caused by a high-fat diet.

Source

Food or pharmaceutical compositions with specific strains of lactic acid bacteria (Lactobacillus fermentum TSF331 and Lactobacillus reuteri TSR332) that can be used to reduce blood uric acid concentration. The compositions can be administered to help prevent and treat conditions like hyperuricemia and gout. The compositions contain strains that have been shown to degrade purine and lower uric acid levels.

Source

Compositions and methods for treating type 1 diabetes using genetically modified lactic acid bacteria expressing IL-2 and a type 1 diabetes-specific antigen. The bacteria are orally administered to deliver low-dose IL-2 and antigen to the gut mucosa, stimulating regulatory T cells to suppress autoimmunity and reverse established type 1 diabetes.

Source

Genetically engineered bacteria that can reduce hyperphenylalaninemia in mammals like humans. The bacteria are designed to produce a modified version of the enzyme phenylalanine ammonia lyase (PAL) that better metabolizes phenylalanine. This allows the bacteria to break down excess phenylalanine in the gut and reduce blood levels. It could offer a novel treatment option for phenylketonuria (PKU) and other disorders associated with high phenylalanine. The engineered bacteria may be orally administered to provide a long-term, natural protein-friendly approach to reducing phenylalanine.

Source

Compositions containing a mixture of microorganisms like bacteria, yeasts, and fungi for reducing blood urate levels as a treatment and prevention strategy for urate-related diseases like gout and hyperuricemia. The compositions aim to balance the gut microbiota by increasing uricase activity and reducing xanthine oxidase activity. This can be achieved using specific strains that inhibit xanthine oxidase and/or express uricase.

Source

A Lactobacillus plantarum strain that can lower blood glucose levels and has antioxidant activity. It's used in compositions like food, medical, and cosmetic products to help prevent and treat diabetes and provide antioxidant benefits. The strain, Lactobacillus plantarum MG4229, is isolated from food and has characteristics like acid and bile tolerance, hydrophobicity, and enzyme production.

Source

A composition for preventing and treating lipid-related metabolic diseases such as fatty liver, diabetes, and obesity. It contains Lactobacillus plantarum ATG-K2 or ATG-K6 strains isolated from fermented vegetables. The composition can be used as a health supplement or functional food to improve markers of liver health, lipid metabolism, obesity, and diabetes. It provides a natural and effective treatment option for lipid-related metabolic disorders.

Source

Using certain bacteria and their metabolites to prevent or treat inflammation-related diseases like diabetes, autoimmune conditions, cardiovascular disease, and inflammatory disorders. The specific bacteria are Desulfovibrio species like Desulfovibrio piger, and the metabolites include 6-bromotryptophan. Administering these agents can reduce inflammation and severity of these diseases.

Source

Probiotic compositions and methods for improving metabolic health and preventing obesity related disorders. The compositions contain specific strains of gut bacteria including Eubacterium eligens, Intestinimonas massiliensis, Prevotella copri, and certain Akkermansia species. Administering these compositions can help treat or prevent obesity, diabetes, metabolic syndrome and related conditions.

Source

Microorganisms and extracts thereof that reduce liver fat content, inhibit lipogenesis, promote fat oxidation, reduce body fat, and increase AMPK phosphorylation when contacted with liver or fat cells. The microorganisms are Lactobacillus strains LMT15-14 and LMT19-1.

Source

Feeding infants a nutritional composition containing Bifidobacterium breve and non-digestible oligosaccharides early in life to prevent metabolic disorders like fatty liver disease, hypercholesterolemia, and atherosclerosis later in life. The composition promotes healthy lipid metabolism and liver function when challenged with a high fat diet by modulating gene expression pathways. The Bifidobacterium breve probiotic and oligosaccharides combination can be added to infant formula to mimic breast milk benefits for long-term metabolic health.

Source

Early life nutritional intervention to prevent obesity, diabetes and chronic inflammation. Administering bifidobacterium breve and non-digestible oligosaccharides to infants results in lower insulin levels, improved insulin sensitivity, and reduced inflammation when challenged with a Western diet later in life. The combination programs infants to better withstand risks associated with a Western diet, preventing hyperinsulinemia, insulin resistance, diabetes, and chronic inflammation.

Source

A Lactobacillus Plantarum strain (Accession No. KCTC 14107BP) that can inhibit fat accumulation in white adipose tissue, brown adipose tissue, and liver tissue. The strain also reduces blood glucose levels, improves glucose tolerance, and ameliorates insulin resistance.

Source

Food and pharmaceutical compositions containing specific strains of lactic acid bacteria that can modulate blood glucose levels and help prevent and treat diabetes. The compositions contain strains of Lactobacillus reuteri, Lactobacillus salivarius, Lactobacillus acidophilus, and Lactobacillus johnsonii. Administering these compositions can help lower blood glucose levels. The strains have been deposited in culture collections.

Source

Using bacterial probiotics that produce AhR receptor agonists to prevent and treat metabolic syndrome and obesity. The probiotics stimulate the Aryl hydrocarbon receptor (AhR) pathway which is impaired in metabolic syndrome. AhR agonists improve weight, glucose control, and fatty liver disease in animal models of obesity. The agonists also show promise in human studies. The invention involves using AhR agonist-producing probiotics or AhR agonists themselves to activate the pathway and treat metabolic syndrome and obesity.

Source

Microbe-based therapies for treating disorders like neurological and metabolic conditions, by modulating the microbiome to produce beneficial metabolites like SCFAs. The therapies involve administering purified populations of microbes that increase butyrate production in the subject. The microbes can modulate neural, hormonal, and metabolic pathways to treat the disorders. The compositions can be administered orally in pill form and are useful after antibiotic treatments to restore a healthy microbiome. The compositions can be customized based on a subject's microbiome sequencing.

Source

Using the bacterium strain Pediococcus acidilactici to regulate blood glucose levels and prevent or treat hyperglycemia. Administering this bacterium orally in a composition as a probiotic has been shown to lower blood glucose levels and prevent hyperglycemia in animal models.

Source